Sotos Syndrome Is Associated with Deregulation of the MAPK/ERK-Signaling Pathway

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Visser, Remco ^a   Landman, Ellie B M ^b   Goeman, Jelle ^a   Wit, Jan M ^a   Karperien, Marcel ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MIRA Institute for Biomedical Technology and Technical Medicine   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 13; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; RAS INTERACTING PROTEIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BODY GROWTH; BONE MATURATION; CARTILAGE CELL; CELL DIFFERENTIATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; EPIPHYSIS PLATE; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HYPERTROPHY; HYPOCHONDROPLASIA; MOLECULAR PATHOLOGY; NOONAN SYNDROME; NSD1 GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SHORT STATURE; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SOTOS SYNDROME; UPREGULATION;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; SKIN; SOTOS SYNDROME; UP-REGULATION;

EID: 84869116491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049229     Document Type: Article

References (40)

1. Tatton-Brown K, Douglas J, Coleman K, Baujat G, Cole TR, et al. (2005) Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. Am J Hum Genet 77: 193-204.
2. Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, et al. (2002) Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30: 365-366.
3. Huang N, vom BE, Garnier JM, Lerouge T, Vonesch JL, et al. (1998) Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J 17: 3398-3412.
4. Rayasam GV, Wendling O, Angrand PO, Mark M, Niederreither K, et al. (2003) NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J 22: 3153-3163.
5. Lucio-Eterovic AK, Singh MM, Gardner JE, Veerappan CS, Rice JC, et al. (2010) Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function. Proc Natl Acad Sci U S A 107: 16952-16957.
6. Qiao Q, Li Y, Chen Z, Wang M, Reinberg D, et al. (2011) The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem 286: 8361-8368.
7. Lu T, Jackson MW, Wang B, Yang M, Chance MR, et al. (2010) Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 107: 46-51.
8. Wang GG, Cai L, Pasillas MP, Kamps MP, (2007) NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 9: 804-812.
9. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, et al. (2009) Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci U S A 106: 21830-21835.
10. De Boer L, Van Duyvenvoorde HA, Willemstein-Van Hove EC, Hoogerbrugge CM, Van Doorn J, et al. (2004) Mutations in the NSD1 gene in patients with Sotos syndrome associate with endocrine and paracrine alterations in the IGF system. Eur J Endocrinol 151: 333-341.
11. de Boer L, Kant SG, Karperien M, van Beers L, Tjon J, et al. (2004) Genotype-phenotype correlation in patients suspected of having sotos syndrome. Horm Res 62: 197-207.
12. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
13. Gautier L, Cope L, Bolstad BM, Irizarry RA, (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315.
14. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
15. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC, (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20: 93-99.
16. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
17. Bake S, Ma L, Sohrabji F, (2008) Estrogen receptor-alpha overexpression suppresses 17beta-estradiol-mediated vascular endothelial growth factor expression and activation of survival kinases. Endocrinology 149: 3881-3889.
18. Chergui F, Chrétien AS, Bouali S, Ramacci C, Rouyer M, et al. (2009) Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer. Clin Chem 55: 1327-1336.
19. Voth DE, Heinzen RA, (2009) Sustained activation of Akt and Erk1/2 is required for Coxiella burnetii antiapoptotic activity. Infect Immun 77: 205-213.
20. Emons J, Chagin AS, Hultenby K, Zhivotovsky B, Wit JM, et al. (2009) Epiphyseal fusion in the human growth plate does not involve classical apoptosis. Pediatr Res 66: 654-659.
21. Mitin NY, Ramocki MB, Zullo AJ, Der CJ, Konieczny SF, et al. (2004) Identification and characterization of rain, a novel Ras-interacting protein with a unique subcellular localization. J Biol Chem 279: 22353-22361.
22. Filzmoser P, Maronna R, Werner M (2008) Outlier identification in high dimensions. Computational Statistics & Data Analysis 52: 1694-1711. DOI 10.1016/j.csda.2007.05.018.
23. van der Eerden BC, Karperien M, Wit JM, (2003) Systemic and local regulation of the growth plate. Endocr Rev 24: 782-801.
24. Kim EK, Choi EJ, (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405.
25. Bentires-Alj M, Kontaridis MI, Neel BG, (2006) Stops along the RAS pathway in human genetic disease. Nat Med 12: 283-285.
26. Tsai CA, Wang SJ, Chen DT, Chen JJ, (2005) Sample size for gene expression microarray experiments. Bioinformatics 21: 1502-1508.
27. Duno M, Skovby F, Schwartz M, (2007) Leukocyte cDNA analysis of NSD1 derived from confirmed Sotos syndrome patients. Ann Hum Genet 71: 713-718.
28. Kamp GA, Ouwens DM, Hoogerbrugge CM, Zwinderman AH, Maassen JA, et al. (2002) Skin fibroblasts of children with idiopathic short stature show an increased mitogenic response to IGF-I and secrete more IGFBP-3. Clin Endocrinol (Oxf) 56: 439-447.
29. Vidarsdottir S, Walenkamp MJ, Pereira AM, Karperien M, van Doorn J, et al. (2006) Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. J Clin Endocrinol Metab 91: 3482-3485.
30. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, et al. (2006) Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 91: 1826-1831.
31. Fang P, Schwartz ID, Johnson BD, Derr MA, Roberts CT Jr, et al. (2009) Familial short stature caused by haploinsufficiency of the insulin-like growth factor i receptor due to nonsense-mediated messenger ribonucleic acid decay. J Clin Endocrinol Metab 94: 1740-1747.
32. Quatela SE, Philips MR, (2006) Ras signaling on the Golgi. Curr Opin Cell Biol 18: 162-167.
33. Mor A, Philips MR, (2006) Compartmentalized Ras/MAPK signaling. Annu Rev Immunol 24: 771-800.
34. Ornitz DM, Marie PJ, (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16: 1446-1465.
35. Ornitz DM, (2005) FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16: 205-213.
36. Wang Y, Spatz MK, Kannan K, Hayk H, Avivi A, et al. (1999) A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci U S A 96: 4455-4460.
37. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM, (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12: 390-397.
38. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P, (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84: 911-921.
39. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, et al. (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 13: 1361-1366.
40. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, et al. (2004) Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 18: 290-305.